Stay updated with breaking news from Clostridioides Difficile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frontiers in Microbiology Publishes Article Detailing Novel Microbiome-based Biomarker of Post-Antibiotic Disruptions in Gut Microbiota.
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) over placebo. RBX2660 is an investigational, potential first-in-class microbiota-based live biotherapeutic